ampakine

Also found in: Wikipedia.

ampakine

An AMPA-type glutamine receptor agonist (e.g., CX516) which facilitates synaptic transmission by binding to glutamate and enhancing long-term potentiation, a critical component in memory. Amakines enhance the activity of AMPA receptor-rich neurons by amplifying neural signals, and are reported to improve memory in early trials in Alzheimer’s disease and schizophrenia.

ampakine

Neuropharmacology Any compound that facilitates synaptic transmission by binding to glutamate and enhance long-term potentiation, a critical component in long term memory, by enhancing the activity of AMPA receptor-rich neurons which enhance AMPA receptor activity by amplifying neural signals generated by glutamate binding; ampakines improve memory in early trials in Alzheimer's disease, schizophrenia See AMPA receptor, Long-term potentiation.

Mentioned in ?

References in periodicals archive ?

These patents are key for developing the AMPAKINE technology for the potential treatment of a variety of clinical indications."

Cortex Pharma receives notice of allowance of European patent

Additionally, the companies have signed a memorandum of understanding (MOU) for the rights to the AMPAKINE CX1739 for neurodegenerative diseases in South Korea.

Cortex Pharmaceuticals Inc concludes second private placement with Samyang Value Partners Co Ltd

29 March 2010 - US-based developer of small molecule compounds Cortex Pharmaceuticals Inc (OTC: CORX) announced on Friday that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.

Cortex sells selected AMPAKINE compounds to Biovail

(Irvine, CA; 949-727-3157) announced that it has received three patents and three notices of allowances for patents in its AMPAKINE program.

Cortex receives additional Ampakine patents and notices of allowance

Cortex Pharmaceuticals Inc awarded US patent for AMPAKINE molecules for respiratory depression

"Cortex and its collaborators at UC Irvine are in the process of initiating a long term experiment in which rats will receive an AMPAKINE in their drinking water for four to eight months.

Cortex' ampakines increase neurotrophin expression

Cortex awarded patent for the use of AMPAKINE molecules to treat respiratory depression

For example, treatment of healthy human subjects with an ampakine, which enhances LTP, improved performance in a dose-dependent manner.

Monitoring and manipulating brain function: new neuroscience technologies and their ethical implications

There also is evidence that ampakine, an investigational drug that modulates glutaminergic alpha-amino-3-hydroxy-5methylisoxazole-4-propionic acid (AMPA) receptor activity, improves "many domains of cognitive function," Dr.

Cognitive deficits affect 85% of schizophrenics. (Deficits are Often Profound)

The team, led by Lynch, Julie Lauterborn, and Linda Palmer, wanted to know whether dendritic retraction was already underway in 13-month-old or "middle-aged" rats and, if it was, could they reverse it by giving rats a compound called an ampakine. Ampakines had previously been shown to improve age-related cognitive deficits in rats as well as increase production of a key growth factor, brain-derived neurotrophic factor (BDNF) in the brain.

Drug Prevents Key Age-Related Brain Change in Rats

Cortex Pharmaceuticals added that the proceeds may be used to support its clinical development of ampakines for the treatment of central sleep apnea and opiate induced respiratory depression, commencing with a Phase 2A clinical study of CX1739, the lead ampakine, as well as to fund corporate general and administrative costs.

Cortex Pharmaceuticals raises USD721,180 from initial closing of private placement

Katz, "Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome," The Journal of Neuroscience, vol.